Overview

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded to chemotherapy and radiation, and gene expression patterns related to outcomes in patients with locally advanced lung cancer who receive this treatment regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Aventis Pharmaceuticals
Treatments:
Carboplatin
Docetaxel